Melanoma/Skin Cancer News

The Parker Institute for Cancer Immunotherapy presented $4.5 million in fellowship and scholarship awards to nine graduate and postdoctoral researchers.

Topical synthetic hypericin ointment, activated with visible light, shows efficacy in reducing mycosis fungoides-cutaneous T-cell lymphoma lesions, according to a phase 3 study.

Jedd Wolchok, MD, PhD, FASCO, has been appointed director of Meyer Cancer Center at Weill Cornell Medicine.

Oncology clinical trials appeared to recover from declines in enrollment and activation during the early phase of the COVID-19 pandemic, according to a study of data from two large academic centers published in Annals of Oncology.

Delays in melanoma treatment are associated with overall and melanoma-specific mortality, according to a study.

Interleukin-6 blockade appeared effective against immune-related adverse events among a small cohort of patients treated with immune checkpoint inhibitors for melanoma, according to study results published in Cancer Cell.

Various sociodemographic and socioeconomic factors, including race/ethnicity and insurance status, correlated with receipt of immunotherapy among patients with melanoma and kidney and lung cancers.

Adjunctive use of reflectance confocal microscopy for suspect melanoma lesions reduces unnecessary excisions, according to results from a clinical trial published in JAMA Dermatology.

Active systemic cancer treatment did not appear associated with increased mortality among patients with cancer and COVID-19, according to study results published in JAMA Network Open.

Vaccinated patients with cancer had significantly higher risks for breakthrough COVID-19 infection, especially those undergoing active cancer care, compared with individuals without cancer, according to a study published in JAMA Oncology.